Last reviewed · How we verify
Glutamine and Fish Oil Supplementation
Glutamine and Fish Oil Supplementation is a Small molecule drug developed by Columbia University. It is currently in Phase 2 development.
At a glance
| Generic name | Glutamine and Fish Oil Supplementation |
|---|---|
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure (PHASE2, PHASE3)
- Nutrition for Colorectal Cancer Patients and Neutrophil Functions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glutamine and Fish Oil Supplementation CI brief — competitive landscape report
- Glutamine and Fish Oil Supplementation updates RSS · CI watch RSS
- Columbia University portfolio CI
Frequently asked questions about Glutamine and Fish Oil Supplementation
What is Glutamine and Fish Oil Supplementation?
Glutamine and Fish Oil Supplementation is a Small molecule drug developed by Columbia University.
Who makes Glutamine and Fish Oil Supplementation?
Glutamine and Fish Oil Supplementation is developed by Columbia University (see full Columbia University pipeline at /company/columbia-university).
What development phase is Glutamine and Fish Oil Supplementation in?
Glutamine and Fish Oil Supplementation is in Phase 2.